Buy PT-141 Peptide (Bremelanotide) 10 mg | ≥99% Purity Cyclic Heptapeptide | SourceTides

When researchers buy PT-141 Peptide (Bremelanotide) from SourceTides, they receive the most clinically validated central melanocortin agonist available for laboratory research — supplied at ≥99% purity, confirmed by reverse-phase HPLC and mass spectrometry on every production batch. PT-141, known generically as bremelanotide and approved by the FDA in 2019 under the brand name Vyleesi, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that operates through a mechanism entirely distinct from all other sexual function research compounds: it engages central nervous system melanocortin receptors — specifically MC3R and MC4R in the hypothalamus and limbic system — rather than acting through peripheral vascular pathways as PDE5 inhibitors do.

PT-141 Bremelanotide is the only melanocortin receptor agonist to hold FDA approval (NDA 210557), and the only peptide in the sexual dysfunction research category backed by Phase III randomised controlled trial data from the RECONNECT trials (n=1,247). Researchers looking to order PT-141 Bremelanotide online for melanocortin system biology, central nervous system sexual arousal models, or neuroendocrine pathway studies gain access to an unusually well-characterised peptide with a public pharmacology dataset generated by the FDA approval process — including full receptor binding characterisation, metabolite profiling, pharmacokinetic studies across multiple species, haemodynamic studies, and behavioural pharmacology.

Every SourceTides PT-141 vial ships with a batch-specific Certificate of Analysis (CoA) and cold-chain packaging. This product is supplied exclusively for in-vitro and laboratory research purposes only and is not approved for general use outside the specific FDA-approved indication (premenopausal women with HSDD, as Vyleesi).

Buy PT-141 Peptide (Bremelanotide) — Full Technical Specifications

The following table provides the complete physicochemical and handling parameters required before designing any PT-141 Bremelanotide research protocol.

Buy PT-141 Peptide Online — What Is Bremelanotide and Why Is It Research-Significant?

PT-141 Bremelanotide has an origin story unlike most research peptides. In the early 1990s, researchers at the University of Arizona were investigating melanotan peptides — analogs of α-MSH originally developed for sunless tanning by activating skin melanocytes. During early human trials of melanotan II, investigators observed unexpected, prominent sexual arousal effects that had nothing to do with pigmentation. That serendipitous finding redirected years of melanocortin biology research toward sexual function. The pharmaceutical team at Palatin Technologies isolated the specific CNS-active fragment responsible — creating PT-141 as a refined, purified cyclic heptapeptide designed to maximise melanocortin receptor engagement relevant to sexual response while minimising melanogenic side effects. (Wikipedia — Bremelanotide identity and development history)

What makes PT-141 structurally distinctive is its cyclic lactam architecture. Rather than a linear peptide chain, the seven amino acids are joined in a closed ring via a lactam bond between the aspartate and lysine side chains. This ring structure confers exceptional metabolic stability compared to linear α-MSH fragments — the peptide resists proteolytic degradation in a way that a linear chain of the same residues would not — making it a far more tractable research tool for in-vivo behavioural and pharmacological studies. The norleucine (Nle) residue at position 1 (substituting for methionine found in the parent α-MSH) provides an additional stability benefit by eliminating the methionine sulfoxide formation that would otherwise occur under storage or physiological oxidative conditions. (Loti Labs — PT-141 melanocortin receptor pharmacology guide)

The critical research distinction for PT-141 Bremelanotide versus all traditional sexual function pharmacological tools: it works centrally, not peripherally. PDE5 inhibitors (sildenafil, tadalafil) achieve their effects by blocking phosphodiesterase-5 in penile vascular smooth muscle, increasing local blood flow. They require existing vascular capacity and intact neural arousal signals to work. PT-141 targets the upstream neural signals themselves — engaging MC4R and MC3R circuits in the hypothalamus and limbic system that govern sexual motivation and desire — making it uniquely valuable for studying the central neural architecture of sexual arousal independent of peripheral vascular biology.

PT-141 Bremelanotide Mechanism of Action — The Melanocortin System Explained

To understand PT-141 peptide research, the five-member melanocortin receptor family requires contextualisation. Each receptor has a distinct anatomical distribution and functional role, and PT-141’s selectivity profile determines which biological processes it engages.

The Five Melanocortin Receptors — PT-141’s Selectivity Profile

Source: Receptor selectivity data from Ki competitive binding characterisation; PT-141 pharmacology characterised in NDA 210557 submissions and Loti Labs melanocortin receptor research guide.

MC4R and Sexual Function — The Genetic Evidence

The centrality of MC4R in sexual function is not merely pharmacological inference — it has been demonstrated by genetic ablation. MC4R knockout mice show markedly impaired erectile function in males and reduced sexual receptivity in females, establishing MC4R as a key mediator of centrally-regulated sexual arousal in preclinical models. This makes PT-141’s MC4R agonism the mechanistic basis for its documented effects in both the preclinical and Phase III clinical literature. MC4R is most densely expressed in the paraventricular nucleus (PVN) of the hypothalamus — the primary integrating centre for autonomic, neuroendocrine, and behavioural responses including sexual motivation. (Spartan Peptides — PT-141 MC4R and PVN mechanism review)

MC4R Activation Cascade — From Receptor to Behaviour

When PT-141 Bremelanotide binds MC4R, it activates adenylyl cyclase through the Gs protein pathway, elevating intracellular cAMP in hypothalamic and limbic neurons. This cAMP elevation modulates neuronal excitability in circuits involved in sexual motivation and reward, activates downstream protein kinase A (PKA) signalling, and modulates melanocortin-receptor-mediated gene transcription in neurons of the paraventricular nucleus and medial preoptic area. Downstream from MC4R activation, dopaminergic and oxytocinergic pathways are engaged — particularly in limbic reward circuits — and central nitric oxide release occurs through CNS neuronal pathways (distinct from the peripheral NOS mechanism exploited by PDE5 inhibitors). This multi-layer central signalling cascade produces the appetitive and motivational components of sexual arousal rather than the peripheral erectile reflex alone. (Cenexa Labs — PT-141 cAMP/dopamine/NO mechanism)

Blood-Brain Barrier Penetration

PT-141 Bremelanotide crosses the blood-brain barrier, as documented in rodent brain distribution studies where peak brain concentration at approximately 40 minutes post-intraperitoneal injection has been measured. This BBB penetration is a defining pharmacological property that enables the central melanocortin receptor engagement responsible for PT-141’s CNS mechanism — and distinguishes it from peripheral-acting compounds that cannot access hypothalamic targets.

PT-141 Bremelanotide Research Areas — Clinical Evidence Summary Table

PT-141 Peptide Clinical Evidence — The RECONNECT Phase III Trials

The RECONNECT trials are the evidentiary foundation for PT-141 Bremelanotide’s FDA approval and the most rigorous clinical dataset available for any research peptide in the sexual function category. Two identical Phase III randomised, double-blind, placebo-controlled trials enrolled a combined 1,267 premenopausal women diagnosed with acquired, generalised hypoactive sexual desire disorder (HSDD). Participants self-administered bremelanotide 1.75 mg subcutaneous injection or identical placebo on an as-needed basis approximately 45 minutes before anticipated sexual activity.

The primary endpoints were change from baseline in satisfying sexual events (SSEs) and in sexual desire score on the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSDS-DAO) subscale. Both trials demonstrated statistically significant improvements on both co-primary endpoints: approximately 0.5 additional satisfying sexual events per month versus placebo, and significant improvement in desire scores and reduction in desire-related personal distress. The FDA advisory committee voted 14-2 in favour of approval. (PMC — RECONNECT Phase III trial results)

Research context note: the magnitude of effect (0.5 additional SSEs/month) is modest in absolute terms, which is consistent with the inherent complexity of sexual desire disorders where psychological and relational factors contribute substantially. The trial design itself — as-needed self-administration, validated patient-reported outcome instruments, placebo-controlled — generates the highest-quality evidence type possible for this indication and provides the field with a robust benchmark against which other melanocortin pathway interventions can be measured.

PT-141 Bremelanotide Research in Male Erectile Dysfunction — Where Does the Evidence Stand?

One of the most active investigational areas for PT-141 peptide research is male erectile dysfunction, particularly in populations where PDE5 inhibitors provide incomplete response. The Phase II clinical trial by Diamond and colleagues (2006, Journal of Sexual Medicine, PMID: 17100927) enrolled men with erectile dysfunction and demonstrated that 67% of PT-141 recipients reported improved erections versus 33% in the placebo group (p<0.01), with sustained improvement across an 8-week treatment period.

The mechanistic rationale for PT-141’s utility in PDE5-resistant erectile dysfunction is particularly compelling: because PT-141 acts centrally on motivational and arousal circuits rather than peripherally on vascular smooth muscle, it addresses the neural arousal signal upstream of the pathway that PDE5 inhibitors amplify. Men who fail PDE5 inhibitors due to insufficient or absent central arousal signalling — rather than inadequate vascular response — represent a population where MC4R agonism may provide mechanistically distinct benefit. This is now being formally evaluated in Phase III trials by Palatin Technologies, announced in 2025 for male ED including PDE5-resistant populations. (Men’s Reproductive Health — PT-141 for men, Phase III 2025)

What Types of Research Is PT-141 Bremelanotide Peptide Most Relevant For?

Researchers across several neuroscience and pharmacology disciplines study PT-141 as a melanocortin system probe. The following table outlines the primary research contexts and why PT-141 specifically serves each domain.

PT-141 Bremelanotide Pharmacokinetics — Half-Life, Onset and Research Protocol Implications

PT-141 Bremelanotide has a well-characterised pharmacokinetic profile from Phase III clinical studies, providing researchers with reliable parameters for protocol design.

PT-141 Bremelanotide Side Effects — What the Clinical Trial Data Shows

Because researchers designing PT-141 preclinical protocols need to select appropriate safety endpoints, and because balanced content reflects E-E-A-T quality standards, the following adverse event data is drawn directly from the RECONNECT Phase III trials and FDA prescribing information. All data is from the FDA-approved human indication and should not be interpreted as product claims by SourceTides.

Buy PT-141 Peptide vs Other Sexual Function Research Compounds — Mechanistic Comparison

Understanding how PT-141 Bremelanotide differs from other compounds studied in the same therapeutic area is essential for selecting the right tool for a given research question.

High-Purity PT-141 Bremelanotide for Sale — SourceTides Quality Control

PT-141’s cyclic lactam architecture requires specialised SPPS protocols with on-resin cyclisation chemistry to form the aspartate-lysine lactam bond correctly. Linear synthesis of the same 7 residues without cyclisation would produce a pharmacologically inactive compound — verifying the ring closure by mass spectrometry is therefore essential, not optional. The Nle substitution at position 1 also requires confirmation, as a methionine-containing analog (the uncorrected predecessor) would show oxidation over time and altered receptor kinetics.

PT-141 Bremelanotide Regulatory and Legal Status — 2025 Overview

View SourceTides’ full shipping and compliance policy.

PT-141 Bremelanotide Peer-Reviewed Research References

Frequently Researched Alongside PT-141 Bremelanotide — SourceTides Catalogue

• Tesamorelin — GHRH analog with Phase III clinical data; GH-axis and metabolic research
• MOTS-c — Mitochondria-derived peptide; metabolic and aging research
• BPC-157 (Body Protection Compound-157) — GI and musculoskeletal repair research
• TB-500 (Thymosin Beta-4 Fragment) — Actin regulation and tissue repair research
• Ipamorelin — GH secretagogue; GHSR agonist research
• Browse All Research Peptides — Full SourceTides catalogue

Frequently Asked Questions — Buy PT-141 Peptide (Bremelanotide)